Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Background Many patients with major depressive disorder have treatment-resistant depression, defined as no adequate response to two consecutive courses of antidepressants. Some evidence suggests that antiglucocorticoid augmentation of antidepressants might be efficacious in patients with major depressive disorder. We aimed to test the proof of concept of metyrapone for the augmentation of serotonergic antidepressants in the clinically relevant population of patients with treatment-resistant depression. Methods This double-blind, randomised, placebo-controlled trial recruited patients from seven UK National Health Service (NHS) Mental Health Trusts from three areas (northeast England, northwest England, and the Leeds and Bradford area). Eligible patients were aged 18-65 years with treatment-resistant depression (Hamilton Depression Rating Scale 17-item score of ≥18 and a Massachusetts General Hospital Treatment-Resistant Depression staging score of 2-10) and taking a single-agent or combination antidepressant treatment that included a serotonergic drug. Patients were randomly assigned (1:1) through a centralised web-based system to metyrapone (500 mg twice daily) or placebo, in addition to their existing antidepressant regimen, for 21 days. Permuted block randomisation was done with a block size of two or four, stratified by centre and primary or secondary care setting. The primary outcome was improvement in Montgomery-Åsberg Depression Rating Scale (MADRS) score 5 weeks after…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“several studies have prospectively shown that elevated cortisol is a risk factor for subsequent MDD 70-72”
From Major depressive disorder (2016) · cites this paper as [70]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 43 · Cited by 47
Metadata
- Authors
- McAllister-Williams, R. H., Anderson, I. M., Finkelmeyer, A., Gallagher, P., Grunze, H. C. R., Haddad, P. M., Hughes, T., Lloyd, A. J., Mamasoula, C., McColl, E., Pearce, S., Siddiqi, N., Sinha, B. N. P., Steen, N., Wainwright, J., Winter, F. H., Ferrier, I. N., & Watson, S.
- Affiliations
- University of Manchester (GB)
- Cumbria Northumberland Tyne and Wear NHS Foundation Trust (GB)
- Newcastle University (GB)
- Greater Manchester Mental Health NHS Foundation Trust (GB)
- Leeds and York Partnership NHS Foundation Trust (GB)
- University of Leeds (GB)
- Tees, Esk and Wear Valleys NHS Foundation Trust (GB)
- ORCID
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 3
- Issue
- 2
- Pages
- 117-127
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W2210983937
- Semantic Scholar
- 5ebec9d2d620f6a7252015eb69fb6cd2c36878c0
- Cited by
- 47
- References
- 43
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 5 · 2023: 2 · 2022: 1 · 2021: 6 · 2020: 7 · 2019: 3 · 2018: 6 · 2017: 5 · 2016: 4
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (NF-SI-0510-10065)
- National Institutes of Health
- Medical Research Council (MC_G1002454)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- treatment-resistant depression, metyrapone, antidepressant augmentation, major depressive disorder, serotonergic antidepressants, glucocorticoid receptor antagonism, depression remission, antidepressant non-response, Montgomery-Asberg Depression Rating Scale, Hamilton Depression Rating Scale
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Metyrapone, Middle Aged, Treatment Outcome, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s2215-0366(15)00436-8
- The paper
- McAllister-Williams, R. H., Anderson, I. M., Finkelmeyer, A., Gallagher, P., Grunze, H. C. R., Haddad, P. M., Hughes, T., Lloyd, A. J., Mamasoula, C., McColl, E., Pearce, S., Siddiqi, N., Sinha, B. N. P., Steen, N., Wainwright, J., Winter, F. H., Ferrier, I. N., & Watson, S. (2016). Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(15)00436-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.